You are here

Message from the SIOG 2020 Annual Meeting Co-Chairs

The coronavirus pandemic has dramatically affected health care professionals and patients worldwide. This is a very unsettling time for everyone and everywhere. In light of the current circumstances and in abundance of caution, travel and attendance could not return to normal by the time of the 2020 SIOG Annual Conference.

The SIOG 2020 Annual Meeting Online will ensure that the geriatric oncology community continues to connect and collaborate, in times when live attendance is not possible due this serious global health challenge. The pandemic has impacted the treatment and care of our older patients. Join SIOG 2020 and contribute.

The programme will comprise of:

  • A short celebration of the 20th anniversary of SIOG;
  • Presentations from the SIOG Working Group on COVID-19 including discussion of ethical issues;
  • Rapid fire abstracts;
  • Updates in Geriatric Oncology;
  • General Assembly (SIOG members only).

We look forward to seeing you at this meeting and hope that you will enjoy the benefits of the remote session to the fullest.

Kind greetings,

Dr Holly Holmes and Prof KL Cheung
Co-chairs,
SIOG 2020 Annual Meeting Online

 

SIOG 2020 in the media

Article on Cancer.net website - SIOG 2020: New Research in Caring for and Treating People With Cancer Age 60 or Older
The International Society of Geriatric Oncology (SIOG) 2020 Annual Meeting Online was held virtually on October 1. In this podcast, William Dale, MD, PhD, discusses 5 studies evaluating potentially better approaches to caring for and treating people with cancer who are 60 or older.

  is the leading oncology channel committed to improving cancer communication and education with the goal of optimising patient care and outcomes. ecancer's programmes offer the healthcare community a wealth of free resources to support continued professional development. ecancer and SIOG have delivered a series of interviews of SIOG key opinion leaders and conference speakers of the online meeting.
This service has been kindly supported by unrestricted grants from Janssen Oncology.

SIOG 2020 Scientific Committee

Co-chairs

Holly Holmes,
USA
Kwok-Leung Cheung,
UK

Members

Nicolo Matteo Luca Battisti,
UK
Raúl Córdoba Mascuñano,
Spain
Nienke de Glas,
The Netherlands
Theodora Karnakis,
Brazil
Melissa Loh,
USA
Isacco Montroni,
Italy
Lucinda Morris,
Australia
Martine Puts,
Canada
Hans Wildiers,
Belgium

E-Posters

Geriatric Syndromes and Treatment Toxicities in Older Patients with Malignant Gliomas
Andrea Wasilewski

Dealing with the lack of evidence to treat depression in older patients with cancer: French Societies of Geriatric Oncology (SOFOG) and PsychoOncology (SFFPO) Position Paper based on a systematic review
Berengere Beauplet

Referral to Geriatricians among Uruguayan Haematologists
Gimena dos Santos

Exploring how older patients with advanced hematologic malignancies utilize their social network: A qualitative study
Grace DiGiovanni

Older adults (OA) age 70+ experience similar survival outcomes to younger adults (YA) age <70 receiving 2nd line therapy for metastatic CRC (mCRC): analysis of 5289 patients (pts) from the ARCAD Clinical Trials Program
Nadine J Mccleary

Nutritional Risk status predicts overall survival of Elderly Mexican patients with advanced non-small-cell lung cancer (NSCLC)
Saul Campos Gomez

Geriatric screening and assessment among older patients with cancer: Evaluation of long-term patient outcomes in a multicentric prospective cohort study of almost 12,000 patients
Victoria Depoorter

Rapid Fire Abstracts

Extreme Hypofractionation Utilizing Stereotactic Body Radiation Therapy is Well Tolerated in Elderly Prostate Cancer Patients
Monica A Pernia

Prevalence of geriatric syndromes in community-dwelling elderly cancer survivors
Rei Ono

Feasibility and results of a pragmatic geriatric assessment (PGA) in a Brazilian Oncology unit. A plan to bypass the most common obstacles in implementing geriatric assessment to older patients with cancer
Antonio Fabiano Ferreira Filho

Qualitative study of a mobile health exercise intervention for older patients with myeloid neoplasms
Chandrika Sanapala

SIOG gratefully acknowledges contribution of the following companies:

At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries.  Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology.  Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do.

 At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on developing therapies in oncology, rare diseases, rare blood disorders, multiple sclerosis, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.

 

Prescribing information is available here.

EMEA-HAL-20-00065 – DOP: September 2020

The International Society of Geriatric Oncology (SIOG) has organised a webinar on the Impact of COVID-19 on older adults with cancer. SIOG is pleased to have the World Health Organisation fully represented. Public health leaders, speakers from Governments, Ministries of Health and Institutions will join the conversation.

This webinar was held on September 30, 2020 at 2:00-3:00pm CET.

The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults.  Age and cancer diagnosis are significant predictors of adverse outcomes of the COVID-19 infection. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations on the implications of the pandemic on several aspects of cancer care in this age group.The webinar will aim to elucidate the challenges of managing cancer in older individuals during the COVID-19 pandemic and outline relevant policies to address this challenge.

This event was FREE.  Certificate of attendance will be provided upon completion of the Post-Webinar Suryey.

Recording of the SIOG COVID-19 Webinar on the Impact of COVID-19 on older adults with cancer